Novavax announced Tuesday that the European Union granted approval for its protein-based non-mRNA COVID-19 vaccine for those 12 and older.
About a month ago, Novavax’s COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration (FDA) and can be used to immunize people 12 years and older.
“Today’s approval of the only updated protein-based non-mRNA COVID-19 vaccine in the EU is an important milestone as the need for vaccination continues,” said John C. Jacobs, President and Chief Executive Officer, Novavax.
“Novavax is working closely with national authorities to have our updated vaccine delivered and available in Europe in the coming weeks.”
The global company is based in Gaithersburg.
Today, the @EMA_News #CHMP recommended for approval our updated protein-based non-mRNA #COVID19 vaccine in the European Union to protect against emerging variants.
Learn more: https://t.co/YjHijRu6kx pic.twitter.com/osfEtBRfoS
— Novavax (@Novavax) October 31, 2023
Related Post
https://x.com/Novavax/status/1719400206972621296?s=20
